STOCK TITAN
  1. Home
  2. Sec-filings
  3. ORKA
  4. [Form 4] Oruka Therapeutics, Inc. Insider Trading Activity

Oruka Therapeutics (ORKA) SVP exercises 10,000 options and sells 10,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported option exercises and share sales in Oruka Therapeutics, Inc. stock. On 2026-08-13 he exercised options for 10,000 shares of common stock (8,542 at $12.50 and 1,458 at $34.39 per share) and on the same date sold 10,000 shares in multiple transactions at weighted average prices between $104.6734 and $108.4628 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

Positive

  • None.

Negative

  • None.
Insider Agarwal Arjun
Role Senior Vice President, Finance
Sold 10,000 shs ($1.07M)
Approx. gross sale proceeds $1.07M
Approx. exercise cost $157K
Approx. pre-tax spread $910K
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F7 8,542 $0.00 $0.00
Exercise Employee Stock Option (right to buy) F8 1,458 $0.00 $0.00
Exercise Common Stock 8,542 $12.50 $107K
Exercise Common Stock 1,458 $34.39 $50K
Sale Common Stock F1, F2 2,100 $104.6734 $220K
Sale Common Stock F1, F3 2,132 $105.5716 $225K
Sale Common Stock F1, F4 1,268 $106.6255 $135K
Sale Common Stock F1, F5 2,142 $107.7138 $231K
Sale Common Stock F1, F6 2,358 $108.4628 $256K
Holdings After Transaction: Employee Stock Option (right to buy) — 152,709 shares (Direct); Common Stock — 15,312 shares (Direct)
Footnotes (8)
  1. F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.05 to $104.99, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.11 to $106.08, inclusive.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.11 to $107.07, inclusive.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.20 to $108.19, inclusive.
  6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.24 to $108.71, inclusive.
  7. F7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
  8. F8. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Options exercised 10,000 shares Total common shares underlying options exercised on 2026-08-13
Exercise price tranche 1 $12.50 per share Exercise price for 8,542 options into common stock
Exercise price tranche 2 $34.39 per share Exercise price for 1,458 options into common stock
Shares sold 10,000 shares Total common shares sold in multiple transactions on 2026-08-13
Lowest reported sale price $104.6734 per share Weighted average price for one sale tranche of 2,100 shares
Highest reported sale price $108.4628 per share Weighted average price for one sale tranche of 2,358 shares
Rule 10b5-1 plan date February 11, 2026 Date the trading plan governing these sales was entered into
Option expiration dates 2035-01-21 and 2036-01-22 Expiration dates for the two employee stock option grants
Rule 10b5-1 trading plan regulatory
"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
non-derivative financial
"transaction_type: non-derivative for Common Stock sale entries"

FAQ

What did Oruka Therapeutics (ORKA) executive Arjun Agarwal report in this Form 4?
Arjun Agarwal reported exercising options for 10,000 shares of Oruka Therapeutics, Inc. common stock and Selling 10,000 shares in multiple transactions on 2026-08-13, according to the Form 4 filing.

How many Oruka Therapeutics (ORKA) options did Agarwal exercise and at what prices?
Agarwal exercised options covering 10,000 shares, consisting of 8,542 shares at an exercise price of $12.50 per share and 1,458 shares at an exercise price of $34.39 per share.

At what prices did Agarwal sell Oruka Therapeutics (ORKA) shares on 2026-08-13?
He sold 10,000 shares in several trades at weighted average prices between $104.6734 and $108.4628 per share, with detailed price ranges provided in the Form 4 footnotes.

Were Agarwal’s Oruka Therapeutics (ORKA) share sales under a Rule 10b5-1 plan?
Yes. The filing states these sales were effected pursuant to a Rule 10b5-1 trading plan that Agarwal entered into on February 11, 2026, indicating they followed a pre-established schedule.

What vesting terms applied to the Oruka Therapeutics (ORKA) options exercised by Agarwal?
One option covering 8,542 shares vests as to 1/48 of the underlying shares monthly from January 1, 2025, and another for 1,458 shares vests monthly from January 1, 2026, as disclosed in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Agarwal Arjun
(Last)(First)(Middle)
C/O ORUKA THERAPEUTICS, INC.
855 OAK GROVE AVE., SUITE 100
(Street)
MENLO PARK CALIFORNIA 94025
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Senior Vice President, Finance
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/13/2026M8,542A$12.523,854D
Common Stock08/13/2026M1,458A$34.3925,312D
Common Stock08/13/2026S(1)2,100D$104.6734(2)23,212D
Common Stock08/13/2026S(1)2,132D$105.5716(3)21,080D
Common Stock08/13/2026S(1)1,268D$106.6255(4)19,812D
Common Stock08/13/2026S(1)2,142D$107.7138(5)17,670D
Common Stock08/13/2026S(1)2,358D$108.4628(6)15,312D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$12.508/13/2026M8,542 (7)01/21/2035Common Stock8,542$092,917D
Employee Stock Option (right to buy)$34.3908/13/2026M1,458 (8)01/22/2036Common Stock1,458$059,792D
Explanation of Responses:
1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.05 to $104.99, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.11 to $106.08, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.11 to $107.07, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.20 to $108.19, inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.24 to $108.71, inclusive.
7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
8. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
/s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR